These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1306 related articles for article (PubMed ID: 25277997)
1. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD; Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997 [TBL] [Abstract][Full Text] [Related]
2. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284 [TBL] [Abstract][Full Text] [Related]
3. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ; Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717 [TBL] [Abstract][Full Text] [Related]
4. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Zile MR; Jhund PS; Baicu CF; Claggett BL; Pieske B; Voors AA; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD; Circ Heart Fail; 2016 Jan; 9(1):. PubMed ID: 26754625 [TBL] [Abstract][Full Text] [Related]
5. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Packer M; McMurray JJ; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile M; Andersen K; Arango JL; Arnold JM; Bělohlávek J; Böhm M; Boytsov S; Burgess LJ; Cabrera W; Calvo C; Chen CH; Dukat A; Duarte YC; Erglis A; Fu M; Gomez E; Gonzàlez-Medina A; Hagège AA; Huang J; Katova T; Kiatchoosakun S; Kim KS; Kozan Ö; Llamas EB; Martinez F; Merkely B; Mendoza I; Mosterd A; Negrusz-Kawecka M; Peuhkurinen K; Ramires FJ; Refsgaard J; Rosenthal A; Senni M; Sibulo AS; Silva-Cardoso J; Squire IB; Starling RC; Teerlink JR; Vanhaecke J; Vinereanu D; Wong RC; Circulation; 2015 Jan; 131(1):54-61. PubMed ID: 25403646 [TBL] [Abstract][Full Text] [Related]
6. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Voors AA; Gori M; Liu LC; Claggett B; Zile MR; Pieske B; McMurray JJ; Packer M; Shi V; Lefkowitz MP; Solomon SD; Eur J Heart Fail; 2015 May; 17(5):510-7. PubMed ID: 25657064 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961 [TBL] [Abstract][Full Text] [Related]
9. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374 [TBL] [Abstract][Full Text] [Related]
11. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD; J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the Efficacy and Safety of Sacubitril/Valsartan and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients With Reduced Ejection Fraction Combined With Moderate-to-Severe Chronic Kidney Disease. Zhang Z; Chen S; Xu X; Luo G; Huang J J Cardiovasc Pharmacol Ther; 2024; 29():10742484241265337. PubMed ID: 39033432 [No Abstract] [Full Text] [Related]
13. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936 [TBL] [Abstract][Full Text] [Related]
15. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545 [TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction. Kobalava Z; Kotovskaya Y; Averkov O; Pavlikova E; Moiseev V; Albrecht D; Chandra P; Ayalasomayajula S; Prescott MF; Pal P; Langenickel TH; Jordaan P; Rajman I Cardiovasc Ther; 2016 Aug; 34(4):191-8. PubMed ID: 26990595 [TBL] [Abstract][Full Text] [Related]
17. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD; J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129 [TBL] [Abstract][Full Text] [Related]
18. LCZ696 : a new paradigm for the treatment of heart failure? Minguet J; Sutton G; Ferrero C; Gomez T; Bramlage P Expert Opin Pharmacother; 2015 Feb; 16(3):435-46. PubMed ID: 25597387 [TBL] [Abstract][Full Text] [Related]
19. Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. Gori M; Senni M; Claggett B; Liu J; Maggioni AP; Zile M; Prescott MF; Van Veldhuisen DJ; Zannad F; Pieske B; Lam CSP; Rouleau J; Jhund P; Packer M; Pfeffer MA; Lefkowitz M; Shi V; McMurray JJV; Solomon SD JACC Heart Fail; 2021 Sep; 9(9):627-635. PubMed ID: 34246603 [TBL] [Abstract][Full Text] [Related]
20. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. Suematsu Y; Miura S; Goto M; Matsuo Y; Arimura T; Kuwano T; Imaizumi S; Iwata A; Yahiro E; Saku K Eur J Heart Fail; 2016 Apr; 18(4):386-93. PubMed ID: 26749570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]